Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Nicola Cahill
  • Lesley-Ann Sutton
  • Mattias Jansson
  • Fiona Murray
  • Larry Mansouri
  • Rebeqa Gunnarsson
  • Fergus Ryan
  • Karin E Smedby
  • Christian Geisler
  • Gunnar Juliusson
  • Richard Rosenquist
View graph of relations
The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%)IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status.
Original languageEnglish
JournalClinical Lymphoma, Myeloma & Leukemia
Volume12
Issue number3
Pages (from-to)201-6
Number of pages6
ISSN2152-2650
DOIs
Publication statusPublished - 2012

ID: 36545741